Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




MRD Assessed by Multiparameter Flow Cytometry in Transplant-Eligible Myeloma

By LabMedica International staff writers
Posted on 05 Jul 2021
Multiple myeloma (MM) treatment has considerably improved in the past 15–20 years. More...
The current paradigm for transplant-eligible newly diagnosed MM (NDMM) patients consists of induction, stem-cell mobilization and autologous stem-cell transplantation (ASCT), followed by consolidation and/or maintenance.

Currently, minimal residual disease (MRD) assessment is the most sensitive tool to measure the depth of response in MM patients. Indeed, among patients achieving a complete response (CR), MRD-positive patients have an inferior progression-free survival (PFS) and overall survival (OS) compared with MRD-negative ones, and a similar outcome to those achieving a partial response (PR).

A large international team working with Hematologists at the University of Torino (Torino, Italy) conducted an MRD correlative study of a MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every six months during maintenance. Transplant-eligible patients aged ≤65 years were enrolled from February 2011 to April 2014 in 172 European centers. A total of 321 patients before lenalidomide maintenance were evaluated for MRD assessment.

Bone marrow (BM) samples were processed in three European laboratories, applying EuroFlow-based multiparameter flow cytometry (MFC) protocols (eight colors, two tubes) with 10−4−10−5 sensitivity. Data were acquired using a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA). One of the laboratories (Torino) applied a local panel with minor differences in fluorochromes and antibodies; data were acquired using a Navios flow cytometer and analyzed with Kaluza software (Beckman Coulter, Brea, CA, USA).

The clinical scientists reported that at enrollment in the MRD correlative study, 76% (244/321) of patients were MRD-negative. In the intention-to-treat analysis, after a median follow-up of 75 months, 5-year progression-free survival was 66% in MRD-negative versus 31% in MRD-positive patients (Hazard Ratio [HR] = 0.39)), 5-year overall survival was 86% versus 69%, respectively (HR = 0.41). MRD negativity was associated with reduced risk of progression or death in all subgroups, including ISS-III (HR = 0.37) and high-risk fluorescence in situ hybridization (FISH) patients (HR = 0.38).

The authors conclude that their study confirms that MRD status by MFC is a strong prognostic factor in NDMM patients receiving intensification with novel agents or high-dose melphalan (HDM). The achievement of MRD negativity in patients with HR-FISH aberrations was associated with a significantly improved survival, underlining the importance of achieving deep responses in this setting. Finally, lenalidomide maintenance further improved the depth of response in standard-risk patients. The study was published on June 3, 2021 in the journal Blood Cancer Journal.

Related Links:
University of Torino
BD Biosciences
Beckman Coulter



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
8-Channel Pipette
SAPPHIRE 20–300 µL
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.